Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Aringer

Showing results (61-70 of 216) with videos related to

Pageof 22
Sort By:
Case Reports in Medicine|June 2, 2011
Tophaceous gout and renal insufficiency: a new solution for an old therapeutic dilemmaAnne-Kathrin Tausche, Carsten Wunderlich, Martin Aringer
Rheumatic Diseases Clinics of North America|August 9, 2005
Does mixed connective tissue disease exist? YesMartin Aringer, Günter Steiner, Josef S Smolen
Seminars in Nephrology|September 3, 2017
Immunoadsorption in Autoimmune Diseases Affecting the KidneyGeorg Stummvoll, Martin Aringer, Ammon Handisurya, et al.
Rheumatology (Oxford, England)|April 8, 2014
Rituximab therapy in patients with refractory dermatomyositis or polymyositis: differential effects in a real-life populationLeonore Unger, Susanne Kampf, Kirsten Lüthke, et al.
Annals of the Rheumatic Diseases|February 6, 2026
Belimumab induces early and sustained resolution of lupus arthritisNicolai Leuchten, Ioannis Parodis, Ralph Brinks, et al.
Rheumatology (Oxford, England)|May 27, 2025
Interleukin-6 receptor blockade leads to low fibrinogen values as part of their effects on the acute phaseMartin Achleitner, Oliver Tiebel, Nicolai Leuchten, et al.
Clinical Immunology (Orlando, Fla.)|January 8, 2013
Innate immune processes in lupus erythematosusMartin Aringer, Claudia Günther, Min Ae Lee-Kirsch
Lupus Science & Medicine|June 17, 2026
Belimumab induces early and sustained resolution of lupus thrombocytopeniaNicolai Leuchten, Ioannis Parodis, Ralph Brinks, et al.
Annals of the Rheumatic Diseases|March 4, 2020
Response to: 'Do 2019 European League against rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus also indicate the disease activity?' by Teng <i>et al</i>Martin Aringer, Karen Costenbader, Thomas Dörner, et al.
Annals of the Rheumatic Diseases|September 20, 2019
Response to: 'New 2019 SLE EULAR/ACR classification criteria are valuable for distinguishing patients with SLE from patients with pSS' by Assan <i>et al</i>Martin Aringer, Karen Costenbader, Thomas Dörner, et al.
Pageof 22

Showing results (61-70 of 216) with videos related to

Sort By:
Pageof 22
Case Reports in Medicine|June 2, 2011
Tophaceous gout and renal insufficiency: a new solution for an old therapeutic dilemmaAnne-Kathrin Tausche, Carsten Wunderlich, Martin Aringer
Rheumatic Diseases Clinics of North America|August 9, 2005
Does mixed connective tissue disease exist? YesMartin Aringer, Günter Steiner, Josef S Smolen
Seminars in Nephrology|September 3, 2017
Immunoadsorption in Autoimmune Diseases Affecting the KidneyGeorg Stummvoll, Martin Aringer, Ammon Handisurya, et al.
Rheumatology (Oxford, England)|April 8, 2014
Rituximab therapy in patients with refractory dermatomyositis or polymyositis: differential effects in a real-life populationLeonore Unger, Susanne Kampf, Kirsten Lüthke, et al.
Annals of the Rheumatic Diseases|February 6, 2026
Belimumab induces early and sustained resolution of lupus arthritisNicolai Leuchten, Ioannis Parodis, Ralph Brinks, et al.
Rheumatology (Oxford, England)|May 27, 2025
Interleukin-6 receptor blockade leads to low fibrinogen values as part of their effects on the acute phaseMartin Achleitner, Oliver Tiebel, Nicolai Leuchten, et al.
Clinical Immunology (Orlando, Fla.)|January 8, 2013
Innate immune processes in lupus erythematosusMartin Aringer, Claudia Günther, Min Ae Lee-Kirsch
Lupus Science & Medicine|June 17, 2026
Belimumab induces early and sustained resolution of lupus thrombocytopeniaNicolai Leuchten, Ioannis Parodis, Ralph Brinks, et al.
Annals of the Rheumatic Diseases|March 4, 2020
Response to: 'Do 2019 European League against rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus also indicate the disease activity?' by Teng <i>et al</i>Martin Aringer, Karen Costenbader, Thomas Dörner, et al.
Annals of the Rheumatic Diseases|September 20, 2019
Response to: 'New 2019 SLE EULAR/ACR classification criteria are valuable for distinguishing patients with SLE from patients with pSS' by Assan <i>et al</i>Martin Aringer, Karen Costenbader, Thomas Dörner, et al.
Pageof 22